MedTrace Logo

Predictive Value of DNA Mismatch Repair System in Colorectal Cancers

NCT05871567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 403

Last updated 2023-05-24

No results posted yet for this study

Summary

* Microsatellite instable (MSI) tumors represent almost the 15% of all sporadic colorectal cancers (CRCs).
* Literature data show that this unique tumor population appears to be poorly responsive to conventional chemotherapy and conversely reveals excellent results to immunotherapy.
* Our data, as demonstrated by propensity score-matched and win ratio analysis, show that there are no substantial differences between MSI and MSS tumors in early CRC stages treated with surgery alone.
* On the contrary, stable tumors (MSS) did much better than MSI tumors in advanced CRC stages undergoing conventional adjuvant treatment.
* Determination of status of DNA mismatch repair system is crucial in high-risk CRCs to optimize treatment.

Conditions

  • MSI-H Colorectal Cancer

Interventions

PROCEDURE

colorectal resection

potential resective surgery

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    lead OTHER

Principal Investigators

  • Gennaro Galizia, MD · University of Campania 'Luigi Vanvitelli'

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2021-12-31
Completion
2023-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05871567 on ClinicalTrials.gov